Molecular cloning and functional characterization of an ATP-binding cassette transporter OtrC from Streptomyces rimosus by Lan Yu et al.
Yu et al. BMC Biotechnology 2012, 12:52
http://www.biomedcentral.com/1472-6750/12/52RESEARCH ARTICLE Open AccessMolecular cloning and functional characterization
of an ATP-binding cassette transporter OtrC from
Streptomyces rimosus
Lan Yu1,2, Xiangyun Yan1, Long Wang1, Ju Chu1, Yingping Zhuang1, Siliang Zhang1* and Meijin Guo1*Abstract
Background: The otrC gene of Streptomyces rimosus was previously annotated as an oxytetracycline (OTC)
resistance protein. However, the amino acid sequence analysis of OtrC shows that it is a putative ATP-binding
cassette (ABC) transporter with multidrug resistance function. To our knowledge, none of the ABC transporters in
S. rimosus have yet been characterized. In this study, we aimed to characterize the multidrug exporter function of
OtrC and evaluate its relevancy to OTC production.
Results: In order to investigate OtrC’s function, otrC is cloned and expressed in E. coli The exporter function of OtrC
was identified by ATPase activity determination and ethidium bromide efflux assays. Also, the susceptibilities of
OtrC-overexpressing cells to several structurally unrelated drugs were compared with those of OtrC-non-expressing
cells by minimal inhibitory concentration (MIC) assays, indicating that OtrC functions as a drug exporter with a
broad range of drug specificities. The OTC production was enhanced by 1.6-fold in M4018 (P= 0.000877) and 1.4-
fold in SR16 (P= 0.00973) duplication mutants, while it decreased to 80% in disruption mutants (P= 0.0182 and
0.0124 in M4018 and SR16, respectively).
Conclusions: The results suggest that OtrC is an ABC transporter with multidrug resistance function, and plays an
important role in self-protection by drug efflux mechanisms. This is the first report of such a protein in S. rimosus,
and otrC could be a valuable target for genetic manipulation to improve the production of industrial antibiotics.
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Clinical multidrug resistance (MDR) to bactericidal anti-
biotics is driving research into the underlying mechan-
isms of resistance and the discovery of novel drugs. In
the past decade, numerous resistance proteins have
identified, including the ubiquitous ATP-binding cassette
(ABC) family of multidrug transporters [1-6]. These in-
tegral membrane proteins mediate the active extrusion
of antibiotics and toxic compounds from cells. Recent
crystal structure analyses revealed that some ABC-type
multidrug proteins, such as MsbA from E. coli, Vibrio
cholera, and Salmonella typhimurium [5-7] and BtuCD
from E. coli [8], also mediate the import of substrates by
altering the conformation of the transmembrane helices* Correspondence: siliangz@ecust.edu.cn; guo_mj@ecust.edu.cn
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reproduction in any medium, provided the or(TMs) from an ‘outward-facing’ state to an ‘inward-
facing’ state [9]. The ABC transporters represent 2% of
gene products in bacteria and play a critical role in their
adaptation to the environment [10]. Some are involved
in resistance to chemotherapy and, therefore, applied re-
search has increasingly focused on the elucidation of the
transportation mechanism of these proteins [11]. Fur-
thermore, the self-protection afforded by the antibiotic
producers is dependent on its endogenous drug resist-
ance proteins. Therefore, these resistance proteins may
also represent targets for antibiotic production improve-
ment strategies [12,13].
Streptomyces rimosus, well known as an oxytetracyc-
line (OTC) producer, has been investigated at the gen-
etic level over many years, although only two antibiotic
pump genes have been discovered to date: the OTC re-
sistance gene, otrB [14] and a putative ABC transporter
gene, otrC, which has been isolated, sequenced andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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frames (orf ) of the otrC gene encode a putative ABC
transporter ATP-binding subunit and a putative trans-
membrane subunit. OtrC was considered to be a puta-
tive ABC transporter with an OTC resistance function
based on its amino acid sequences, although no evidence
in support of this has been reported to date. Generally,
the location of resistance genes in the chromosome is
close to the corresponding antibiotic biosynthesis clus-
ters. In the case of OTC, the OTC cluster in S. rimosus
is flanked by the resistance genes, otrA and otrB [15],
while otrC is distant from the OTC cluster (data not
published). We hypothesize that otrC plays a role as the
MDR transporter in OTC resistance. Here, we present
evidence that otrC encodes a protein with ATPase and
multidrug efflux activities and therefore may represent a
manipulation target for strategies to improve of OTC
production in S. rimosus.
Results
Conserved motifs analysis and model prediction of otrC
The otrC gene contains two open reading frames
(ORFs), which encode a putative ATP-binding subunit
(OtrC-ORF1) of 38 kDa and a putative transmembrane
subunit (OtrC-ORF2) of 30 kDa. A NCBI BLAST search
of the amino acid sequence of the OtrC protein identi-
fied a number of similar proteins, the majority of whichFigure 1 Alignment of the amino acid sequence of the OtrC-ORF1 reg
that are highly conserved, whereas the residues in light gray are less well cwere ABC components of doxorubicin or MDR ABC
transporters from various phyla.
The ATP-binding subunit usually contains conserved
sequence motifs that play important roles in protein
function. Therefore, an alignment of OtrC-ORF1 with
DrrA [16] and Msr-ORF1 from Streptomyces [17] was
performed for the identification of conserved motifs
(Figure 1). The results showed that OtrC-ORF1 exhibits
41% amino acid identity with the doxorubicin resistance
protein DrrA from S. peucetius and 43% identity with
the multidrug ABC transporter ATP -binding subunit
Msr-ORF1 from S. rochei F20. The N-terminal of OtrC-
ORF1 contains the well-described conserved Walker A
and B motifs and the ABC signature sequence. These
motifs are intimately involved in ATP hydrolysis [18],
which indicates that OtrC belongs to the ABC transporter
superfamily. The alignment also showed the conserved
LDEADQLA and LDEVFL motifs in the C-terminal re-
gion of OtrC-ORF1. These motifs exhibit 58.6% and 80%
identity with those of DrrA and Msr-ORF1, respectively.
However, the CREEM motif was absent from OtrC-ORF1
and Msr-ORF1. The LDEVFL motif is known to be
involved in the doxorubicin-stimulated nucleotide-binding
function and also exists in the MDR protein [18].
Therefore, it was speculated that the ATPase activity of
OtrC-ORF1 is stimulated by doxorubicin and other
drugs.ion with DrrA and Msr-ORF1. The dark gray regions show residues
onserved.
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quence diversity and varies in the total number of trans-
membrane helices. OtrC-ORF2 was then aligned with
other ABC transporters (Figure 2). The conserved EAA
motif (E1AA3RALG7) that is present in MalG was
believed to be present only in the importers of the ABC
family, while the G−2E−1. . .A3R/K4. . .G7 motif present in
BtuC, which has similarity with EAA motif, has been
identified in both the import and export functions of
ABC transporters [19]. The alignment analysis revealed
the present of a G−2. . ..R4 motif that was present in all
ABC transporter proteins with an exporter function, in-
cluding EpeA, DrrB, MsbA and BtuC. The G−2 residue
has been identified to correspond with drug sensitivity
by site-directed mutagenesis [19]. We therefore assumed
that the G−2. . ..R4 motif was involved in the drug export
function of the ABC transporter and OtrC functions as a
drug exporter.
The prediction of the secondary structure of OtrC-
ORF2 by the PROF method using the PredictProtein
program (www.predictprotein.org) indicated the pres-
ence of a N-terminal hydrophobic domain with six puta-
tive α-helical transmembrane segments and cytoplasmic
facing N and C termini. The reported canonical ABC
systems display a modular architecture composed of two
nucleotide-binding domains/subunits and two trans-
membrane domains/subunits. Therefore, it can be con-
cluded that the OtrC system is a tetrameric complex
composed of two homodimeric constituents, similar to
that of many other bacterial ABC transporters [17].
Functional characterization of OtrC
E. coli BL21 (DE3) cells were transformed with the indi-
cated plasmid pETC02 (Additional file 1: Figure S1),
while OtrC expression was induced by IPTG and ana-
lyzed by Coomassie blue staining of the SDS-
polyacrylamide gels (SDS-PAGE) and Western blotting.Figure 2 Alignment of the amino acid sequence of predicted conserv
BtuC and MalG. The dark gray regions show residues that are highly cons
first amino acid in the sequence of each protein is shown.A band that corresponded to the 30-kDa OtrC-ORF2
was detected in the cytoplasmic membrane by SDS-
PAGE (Figure 3); however, although the OtrC-ORF2 was
fused with a His6-tag at the C terminal, the specific band
of the gene product was absent in the Western blot ana-
lysis. This could have been due to the embedding of the
His6-tag by protein folding. The specific band that corre-
sponded to the 68 kDa-OtrC, 38 kDa-OtrC-ORF1 sub-
unit could be visualized in whole cell protein fraction by
SDS-PAGE and Western blot analysis (Figure 3). These
specific bands of OtrC and its subunits were absent from
E. coli that carried the empty pET28a plasmid, which
suggested the successful heterologous expression of
OtrC in E. coli.
The malachite green assay was employed to determine
the ATPase activity of OtrC. The results showed that the
ATPase activity of E. coli/pETC02 (121.3 nMml-1min-1)
was significantly higher than that of E. coli/pET28a
(8.1 nMml-1min-1) (Additional file 1: Figure S2 and
Figure 4), which indicates as expected that OtrC has
ATP hydrolysis activity.
Fluorimetric EB, a cationic substrate of ABC transpor-
ters, was employed for the efflux assays to test if OtrC
can mediate the transport coupled to ATP hydrolysis.
The cells of E. coli transformants were suspended in
20 μM EB solution, and the EB efflux activity was trig-
gered by glucose. As shown in Figure 5A, the energiza-
tion of cells resulted in an increased rate of EB extrusion
for OtrC-expressing cells compared to the control cells,
which indicates that OtrC displays an ATP-dependent
extrusion activity. The efflux activity of OtrC was further
confirmed by determining the effect of an ABC trans-
porter inhibitor orthovanadate on the accumulation of
EB in OtrC-expressing and OtrC-nonexpressing cells. As
the glycolysis pathway also can be inhibited by orthova-
nadate, cells were energized with ATP instead of glucose.
As shown in Figure 5B, orthovanadate increased theed motifs of the transmembrane subunit, OtrC-ORF2, MsbA, DrrB,





























Figure 4 ATPase assay of OtrC-overexpressing and OtrC-
nonexpressing cells. OtrC from S. rimosus was introduced into the
E.coli BL21(DE3) strain using a pETC02 plasmid, and the E.coli BL21
(DE3) carrying the empty pET28a was used as the control. The cells
were induced by 1 mM IPTG at 30°C for 10 h, and then collected by
centrifugation. The cell wall was digested by lysozymes and the
membrane vesicles were harvested by centrifugation. The ATPase
activity of E.coli/pETC02 (dark gray) was determined compared with
to the E. coli/pET28a control (light gray). Vertical error bars
corresponded to the standard error of the mean of three replicated
samples.
Figure 3 OtrC heterologous expression in E. coli. Cultures of cells were grown and induced by 1 mM IPTG as described in the Materials and
Methods. Cells were resuspended in 500 mM Tris–HCl (pH 7.0) buffer, and cell disruption was performed by ultrasonic waves; the total membrane
fractions were harvested by centrifugation at 125,000 rpm at 4°C for 1 h. 12% SDS-PAGE analysis was performed with a high-molecular-weight
protein marker (M), 80 μg total membrane fractions of E. coli/pET28a (lane 1), 40 μg, 60 μg and 80 μg total membrane fractions of E. coli/pETC02
(lane 2,3 and 4), 120 μg total cell protein of E. coli/pET28a (lane 5), 60 μg,80 μg and 120 μg total cell protein of E. coli/pETC02 (lanes 6,7 and 8).
Western blot analysis was performed with equal volumes of total cell protein of E.coli/pET28a (lane 9) and E. coli/pETC02 (lanes 10, 11 and 12),
His-tag mouse and peroxidase-conjugated goat anti-mouse antibodies were used for specific band detection.
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crease was observed in OtrC-nonexpressing cells. These
observations indicate that orthovanadate inhibited the
OtrC-mediated efflux of EB.
Effect of OtrC expression on drug susceptibility
In order to identify the MDR function of OtrC, the
OtrC-overexpressing and non-expressing mutants of the
S. rimosus M4018 strain were constructed and identified
as described in the Materials and Methods (Additional
file 1: Figures S3 and S4).
Several drugs with clinical importance were employed
for drug susceptibility assays of OtrC-overexpressing
and OtrC-nonexpressing strains of E. coli as well as
S. rimosus. As shown in Tables 1 and 2, the MIC for
ampicillin increased by 1.3-fold, and in the order of
3.3 fold for doxorubicin, 2-fold for EB and vancomycin in
E. coli/pETC02 compared with E. coli/pET28a. The
MICs of E. coli/pETC02 to OTC and ofloxacin were
enhanced at 5 μg/ml and 2 μg/ml, respectively; in contrast,
the growth of E. coli/pET28a was completely inhibited by
these drugs. However, the overexpression of OtrC had no
effect on the susceptibility of E. coli to rifampicin, erythro-
mycin and streptomycin (Table 1).
A clear difference in drug sensitivity to these drugs was
also found in S. rimosus mutants M4018/pSEC and
M4018/pKCΔotrC with respect to the control strain
M4018/pSET152. The overexpression of OtrC in M4018/
pSEC resulted in significantly elevated MICs to ampicillin
(3-fold), OTC (1.7-fold), doxorubicin (2-fold), EB (2-fold)and ofloxacin (20-fold). Furthermore, the OtrC overex-
pressing mutant survived with 500 μg/ml vancomycin,
while the growth of M4018/pSET152 was completely
inhibited by vancomycin (Table 2). The MICs for ampicil-
lin and doxorubicin in the OtrC-disrupting mutant
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Figure 5 Ethidium bromide (EB) transport in OtrC-
overexpressing cells and nonexpressing cells. A: The OtrC-
expressing cells (black squares) and the control cells (gray triangles)
were cultured and induced with 1 mM IPTG, and then resuspended
in KPi buffer (pH 7.0) containing 5 mM MgSO4. The de-energized
cells (OD600 = 0.5) were pre-equilibrated with 20 μM EB at 30°C, and
25 mM glucose was added (at the arrow) to initiate EB efflux.
B: The effect of orthovanadate on the accumulation of EB in
OtrC-expressing and nonexpressing cells. E.coli/pETC02 cells were
cultured, induced and collected; the washed cells (OD600 = 0.5) were
incubated for 10 min at 30°C in the presence (dark gray stars) or
absence (black squares) of 0.5 mM orthovanadate, followed by the
addition of 20 μM ethidium bromide (EB) along with 2 mM Mg-ATP
(arrow). The E. coli/pET28a cells were used as the control, treated
with (grey triangles) or without (light gray circles)orthovanadate as
described above. The development of fluorescence of the
DNA-ethidium complex in the cell suspension was monitored at
30°C every 20 s. The fluorescence intensity before the addition of
glucose or ATP was normalized to 100%.
Table 1 Susceptibilities of E. coli mutants to several drugs










‘-’, cell growth was completely inhibited.
Table 2 Susceptibilities of S. rimosus mutants to several
drugs
Antibiotics (μg/ml) M4018/pSET152 M4018/pSEC M4018/pKCΔotrC
Ampicillin 500 1500 100
Rifampicin 200 200 200
Oxytetracycline 1500 2500 1000
Doxorubicin 500 1000 100
Ethidium bromide 4 8 4
Vancomycin 1 500 -
Ofloxacin 20 400 4
Erythromycin 2 2 2
Streptomycin + + +
‘+’, cell growth could not be inhibited by the antibiotic; ‘-’, cell growth was
completely inhibited.
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had no effect on EB and vancomycin sensitivity (Table 2).
Neither the OtrC-overexpressing mutant nor the OtrC-
disrupting mutant showed any alternation in the sensitiv-
ity to rifampicin, erythromycin and streptomycin (Table 1),
which was in agreement with the results of drug suscepti-
bility assays in OtrC-overexpressing E. coli cells.
The otrC overexpressing cells showed a significantly
enhanced MIC to ampicillin, OTC, doxorubicin, EB,
ofloxacin and vancomycin, which indicated that OtrCfunctions as a drug exporter with a broad range of drug
specificities.
OtrC expression affects OTC production in S. rimosus
In order to explore the applications of OtrC for antibiotic
production, the identified recombinant plasmids, pSEC
and pKCΔotrC (Additional file 1: Figures S2 and S3),
were introduced into an industrial OTC overproducer,
SR16, after identification as described in the Materials
and Methods. Mutant strains were used for OTC produc-
tion measurements in addition to the mutant derived
from strain type M4018. The results showed that the mu-
tant M4018/pSEC yielded an OTC production peak of
327.0 μg/ml at 96 h, which was markedly higher than that
of M4018/pSET152 (202.8 μg/ml at 120 h), while the otrC
disruption mutant M4018/pKCΔotrC yielded a decreased
OTC production peak of 170.0 μg/ml at 168 h
(Figure 6A). The OTC production peak in M4018/pSEC
at an earlier time than the controls suggested that the
OTC efflux function of OtrC plays an important role in
self-protective mechanisms and OTC production.
The OTC production profile in SR16 mutants showed
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Figure 6 Specific OTC production of S. rimosus strains. A: An
extra copy of otrC was introduced into the S. rimosus M4018
chromosome using the recombinant integrative vector pSEC (white
circles). The otrC disruption mutant of M4018 was constructed using
the temperature-sensitive recombinant plasmid pKCΔotrC (white
stars). M4018/pSET152 (black squares) served as the control. B: An
extra copy of otrC was introduced into the chromosome of S.
rimosus SR16 using the integrative vector pSEC (white diamonds).
The otrC disruption mutant of SR16 was constructed using the
temperature-sensitive plasmid pKCΔotrC (white hexagons). SR16 that
carried the empty pSET152 plasmid was used as the control (black
triangles). S. rimosus strains were grown in MS plates, spores were
inoculated into GYCS medium to the final concentration of 1 × 106
spores per ml, after which they were cultured at 28°C on a rotary
shaker (260 rpm) for 72 h; 1% seed culture was transferred into SC
medium cultured at 30°C on a rotary shaker (260 rpm) for 7 d. OTC
was measured by HPLC. Vertical error bars correspond to the

















































Figure 7 qRT-PCR analysis of the transcriptional level of otrC in
S. rimosus mutants. A: The transcriptional level of otrC in M4018/
pSEC at 24 h (light gray) and 96 h (dark gray) during OTC
fermentation, where M4018/pSET152 was used as the control. B: The
transcriptional level of otrC in SR16/pSEC at 24 h (light gray) and
72 h (dark gray) during OTC fermentation, SR16/pSET152 was used
as the control. S. rimosus cells were collected at different
developmental stages during culture in fermentation medium. RNA
extraction and quality control is described in the Materials and
Methods. Three housekeeping genes, 16S rRNA, hrdB and zwf1, were
used as the reference genes for qRT-PCR analysis.
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which was 1.4-fold greater than that of SR16/pSET152 at
96 h. In contrast, the production of OTC was markedly
reduced in the disrupted mutant SR16/pKCΔotrC. It
yielded an OTC production rate of 784.2 mg/L at 168 h,
which was approximately 80% of the peak production of
SR16/pSET152 (Figure 6B). These results were in agree-
ment with the above-mentioned conclusion that OtrC ex-
pression efficiently affects OTC production in S. rimosus.
The transcription levels of otrC in otrC-expressing S.
rimosus strains were measured by qRT-PCR. Thetranscription level of otrC was significantly enhanced in
S. rimosus M4018/pSEC compared with the control
strain M4018/pSET152 (Figure 7A), which explains the
significant improvement of OTC production in M4018/
pSEC. For the industrial overproducer SR16, the otrC
duplication mutant SR16/pSEC showed a marked en-
hancement in the transcription of otrC compared with
the negative control, SR16/pSET152 (Figure 7B). These
results suggest that otrC overexpression was responsible
for OTC overproduction in M4018/pSEC and SR16/
pSEC.
Discussion
The bacterial ATP-binding cassette (ABC) family of mul-
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Figure 8 The relative fold change of MICs of OtrC-expressing
cells with different drugs compared to OtrC-nonexpressing
cells. A: The relative change in the MIC of OtrC-expressing E. coli/
pETC02 cells (gray) to ampicillin (A), rifampicin (R), oxytetracycline
(O), doxorubicin (D), ethidium bromide (E), vancomycin (V), ofloxacin
(Of), erythromycin (Er) and streptomycin (S), using the OtrC-
nonexpressing E.coli/pET28a cells (light gray) as the controls. The
relative change in MIC to the drug that could completely inhibit the
cell growth of E.coli/pET28a was set as “0”, while the MIC of drug
which could not inhibit the cell growth was set as “1”. Cells were
grown in LB liquid medium supplemented with kanamycin, IPTG
and different concentrations of test drugs at 37°C, and spun at
170 rpm for 12 h. Cells were then resuspended in fresh LB and
spread immediately on the LB plates with kanamycin, IPTG and
different concentration of the test drugs. The MICs to drugs were
determined after the plates were cultured at 37°C for 12 h. B: The
relative fold of MICs of OtrC-expressing S. rimosus mutants, M4018/
pSET152 (light gray) and M4018/pSEC (gray), to the above-
mentioned drugs, using the OtrC-nonexpressing mutant M4018/
pKCΔotrC (dark gray) as the control. The relative change in the MIC
to drugs that could completely inhibit the cell growth of M4018/
pKCΔotrC was set as “0”, while the MIC of drug which could not
inhibit the cell growth was set as “1”. Cells were grown in TSB liquid
medium supplemented with different concentrations of drugs at
28°C, and the centrifuged at 220 rpm for 30 h, resuspended in fresh
TSB and spread immediately on TSB plates with different
concentrations of test drugs. The MICs of drugs were determined
after the plates were cultured at 28°C for 3 d. ** indicate significantly
higher MIC values than the control cells; * indicate higher MIC
values than the control cells.
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present study, we characterized the function of OtrC, a
putative ABC transporter, from S. rimosus and report
that OtrC has major effects on the overproduction of
OTC in S. rimosus.
The multidrug exporter function of OtrC from S. rimosus
The results of the amino acid sequence alignment ana-
lysis showed that OtrC contains a N-terminal ATPase
activity-related conserved motif and a drug resistance
activity-related motif at the C-terminal (Figure 1). As
the highly conserved LDEVFL motif of DrrA at the C-
terminal was shown to be involved in doxorubicin efflux,
this indicated that OtrC might also be associated with
antibiotic resistance. The present results (Figure 8) show
that drug susceptibility levels to tetracycline, EB and
floxacin were enhanced in strains of E. coli and S. rimo-
sus that overexpressed OtrC compared to corresponding
OtrC-nonexpressing strains, which were very similar
findings to those published previously regarding DrrA
and Msr-ORF1 [4,17]. Additionally, we hypothesized that
the low level of conservation of the amino acid sequence
in the LDEADQLA motif of OtrC-ORF1 (Figure 1) may
be responsible for the consistently low sensitivity to
erythromycin of OtrC-expressing cells.
OtrC-ORF2 contains the G−2. . .R4 conserved motif,
but does not possess the EAA conserved motif (Figure 2).
The former might be involved in drug export function,
and the latter was identified to be involved in import
function [19]. To verify the function of OtrC as a drug
transporter in cells, the E. coli cells that overexpressed
OtrC were given glucose, which resulted in the extrusion
of EB rather than its uptake as was expected (Figure 5).
Furthermore, when the ABC transporter inhibitor ortho-
vanadate was added, EB extrusion was not observed in
the OtrC-expressing cells supplemented with ATP. This
indicated that OtrC is responsible for the EB export ac-
tivity in OtrC-expressing E. coli transformant. Hence,
the drug resistance mechanism of OtrC could be based
on ATP hydrolysis coupled with its transport ability.
The OtrC-expressing E. coli transformant showed sig-
nificantly enhanced susceptibilities to ampicillin, doxo-
rubicin, OTC, EB, vancomycin and ofloxacin (Figure 8A).
However, the MICs of S. rimosus mutants to ampicillin,
OTC, doxorubicin and ofloxacin were markedly amplified
compared with controls (Figure 8B), which suggested that
OtrC could play an important role in the self-protection
mechanisms of S. rimosus. Interestingly, the MIC of
M4018/pSEC to vancomycin was 500 μg/ml, and the
growth of M4018/pKCΔotrC and M4018/pSET152 was
completely inhibited under these conditions. This implies
that OtrC acts as an efficient vancomycin efflux pump.
Additionally, the significantly enhanced vancomycin re-
sistance activity in S. rimosus M4018/pSEC might be
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which results in the overexpression of OtrC during the
early growth phase.
Effect of OtrC expression on OTC production in S. rimosus
The M4018 strain showed a stable production of OTC.
In contrast, the SR16 mutants showed an obvious drop
of OTC production after 3 days, which was probably
due to the instability of SR16 (Figure 7). A red pigment
was observed during SR16 fermentation (date not pub-
lished), which, to our knowledge, has not been previ-
ously described in S. rimosus. We speculate that another
competitive secondary metabolic pathway was activated
in SR16 during the traditional mutation.
The real-time qRT-PCR analysis showed that OtrC
overexpression could lead to a significant OTC produc-
tion improvement by secreting OTC out of cells in both
the M4018 S. rimosus strain and an industrial overpro-
ducer, SR16. Hence, it is reasonable to suggest that otrC
could be a valuable target for genetic manipulation, such
as introducing extra copies of the ABC transporter
[12,13], overexpressing the pathway genes with the use
of transcription regulators [20-22] and the replacement
of heterologous promoters [23,24], in order to yield the
overproduction of OTC.
Conclusion
OtrC is a putative ABC-type transporter in S. rimosus,
although it has been considered to be an OTC resist-
ance protein. However, the drug resistance function
and mechanism of OtrC have not been studied previ-
ously. In this study, the alignment of the amino acid
sequence of OtrC suggested that it could belong to an
ABC superfamily and could act as an ATP-binding
drug exporter, which was further identified by ATPase
activity determination and EB efflux assays in this
study. The results of the drug susceptibility tests
showed that OtrC confers a functional resistance to-
ward a broad range of structurally unrelated drugs.
Hence, OtrC is a multidrug resistance protein based on
an ATP hydrolysis-dependent active efflux mechanism.
It is the first reported multidrug resistance ABC trans-
porter in S. rimosus.
The further investigation of mutations of conserved
amino acid residues that inhibit the OtrC pump could
be valuable for controlling drug resistance in clinically
important pathogens. Improvements in OTC production
were successfully made by introducing an extra copy of
otrC into the high-performance SR16 strain, while the
disruption mutant displayed a decreased OTC yield. This
highlights the potential value of OtrC in OTC industrial
production. Future studies on the OTC efflux activity of
OtrC and the effects of OtrC overexpression in S. rimo-
sus will contribute to improvements in OTC production.Methods
Bacterial strains, plasmids, antibiotics and antibodies
The bacterial strains used in this study were E. coli
DH5α, ET12567 (pUZ8002) [25], BL21 (DE3), S. rimosus
M4018 (a typical strain, gift from Prof. Iain S Hunter,
University of Strathclyde, UK), and SR16 (an industrial
overproducer obtained by traditional strain improve-
ment, Shanxi Tongxing Antibiotic Company, China).
The plasmids used in this study included pMD19-T,
pSET152, pKC1139, pET28a and pSEC (otrC in
pSET152), pKCΔotrC (for otrC disruption, reconstructed
by pKC1139), pETC02 (otrC in pET28a). E. coli strains
were screened using a LB plate with 100 μgml-1 ampicil-
lin, 50 μgml-1 apramycin, 25 μgml-1 kanamycin or
34 μgml-1 chloramphenicol when appropriate. S. rimo-
sus mutants were screened by TSB plates with
500 μgml-1apramycin or 500 μgml-1 kanamycin.
Different concentration of ampicillin, oxytetracycline,
doxorubicin, ethidium bromide, vancomycin, ofloxacin,
rifampicin, erythromycin and streptomycin were used
for the MDR assay with OtrC. His-tag mouse and
peroxidase-conjugated goat anti-mouse IgG (SAB, USA)
antibodies were employed for Western blotting analyses.
Media and growth conditions
Escherichia coli strains were cultured in Luria-Bertani
(LB) medium (1.0% tryptone, 1.0% NaCl, 0.5% yeast ex-
tract) with appropriate antibiotics when necessary. S.
rimosus strains were grown in tryptone soya broth (TSB)
medium (3% tryptone soya broth, Oxoid) for genomic
DNA extraction and mycelium growth, adding appropri-
ate antibiotics, where needed. The mannitol soya flour
(MS) medium (2% mannitol, 2% soya flour and 2% agar)
was used to grow spores [26]. The seed cultures were
obtained by inoculating spores into glucose yeast casein
hydrolysate and sucrose (GYCS) medium (1% glucose,
0.05% yeast extract, 1.5% casein hydrolysate, 0.28% su-
crose, 0.01% CaCO3). Soluble starch and corn steep li-
quor (SC) medium [27] (2% soluble starch, 1% corn
steep liquor, 0.6 (NH4)2SO4, 0.8% CaCO3, 0.5% NaCl,
0.2% soy bean oil, pH 6.8 to 7.2).
OtrC expression in E. coli
For OtrC heterologous expression in E. coli, the gen-
omic DNA of M4018 was used as the template. The
following primers, orf1F (5’CGCCATATGATGAC
GCGAAAGACGATATCCA3’) and orf1R (5’CGCGG
ATCCTCATGCCGGAACCTCCTCG3’), were used to
amplify the otrC open read frame 1 (orf1), which was
introduced into the NdeI and BamHI sites (under-
lined); primers orf2F (5’CGCGGATCCGAAGGAGA
TATACCATGAGTGCCGCGACGGT3’) and orf2R (5’A
TTTGCGGCCGCGGTCTTCTTGCGGAACTTGGC 3’)
were used to amplify otrCorf2 which was introduced
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optimized RBS sites of the T7 promoter (bold) was intro-
duced towards the 5’ end. The amplified fragments (orf1,
1,074 bp and orf2, 870 bp) were subcloned into T-vector
for sequencing, and then digested by restriction enzymes
and cloned into the pET28a vector under the T7 promoter
to construct the recombinant plasmid, pET28a-otrCorf1-
otrCorf2 (pETC02).
After pETC02 was introduced into the E. coli BL21
(DE3) strain, for OtrC expression, the E. coli transformant
(E.coli/pETC02) was cultured in LB medium with 50 μg/
ml kanamycin. The growth of the cultures was monitored
by recording the optical density at 600 nm (OD600); when
it reached at 0.6, cells were induced by isopropyl beta-D-
thiogalactopyranoside (IPTG) at a final concentration of
1 mM at 30°C, at 170 rpm for 10 h. The E. coli/pET28
transformant was cultured and induced under the same
conditions and used as a negative control.
One-milliliter cell suspensions were centrifuged at
12,000 rpm for 10 min at 4°C, and washed with deionized
water, then resuspended in 100 μl Tris–HCl (500 mM
pH 7.0) buffer, and the cell disruption was performed by
ultrasonic waves. The cell disruption suspension was
centrifuged at 12,000 rpm for 15 min at 4°C to remove
the cell debris, and the total membrane fractions were
then harvested by centrifugation at 125,000 rpm, at 4°C
for 1 h. The total protein sample and the membrane frac-
tions were then analyzed by 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting fol-
lowing standard procedures [26].
ATPase assay of OtrC
For the ATPase assay, E. coli transformants were cultured
in LB with 50 μg/ml kanamycin and induced with IPTG,
as described above. A cell suspension sample of 1.5 ml
with OD600 = 0.6 was obtained, and cells were collected
by centrifugation at 10,000 rpm for 1 min. Cells were
then washed with deionized water twice. Cell walls were
digested by incubation for 1 h at 30°C with 10 mg/ml
lysozyme (BBI, UK), after which DNase (100 μg/ml,
TaKaRa, Japan) and 10 mM MgSO4 were then added.
After a 10-min incubation, the suspension was centri-
fuged at 16,000 rpm for 15 min at 4°C to remove the
cellular debris, and the membrane vesicles were then
harvested by centrifugation at 125,000 rpm at 4°C for
1 h, and resuspended in 1.5 ml buffer A (50 mM
Hepes pH 8.0, 250 mM NaCl, 10% glycerol [v/v]), and
used as the protein sample in immediate assays for
ATPase activity [1].
The malachite green assay was used to determine the
specific ATPase activity of OtrC by measuring the re-
lease of inorganic phosphate. Briefly, 2 mM ATP was
added into a 200 μl protein sample, 25-μl aliquots were
transferred into 175 μl of 10 mM sulfuric acid to stopthe reaction for 20 min. Subsequently, 50 μl of fresh
malachite green/molybdate solution was added, and the
absorbance at 650 nm was measured after incubation for
10–15 min [1,28].
The malachite green/molybdate solution was freshly
prepared and it contained malachite green solutions 1
(0.122% [w/v] malachite green, 20% [v/v] sulfuric
acid), solutions 2 (7.5% [w/v] ammonium molybdate)
and solutions 3 (11% [v/v] Tween 20) at a ratio of
50:12.5:1 [1].
Efflux assay of OtrC
The E. coli/pETC02 was cultured in LB with 50 μg/ml
kanamycin and induced with IPTG. Subsequently, the
cells were collected by centrifugation at 10,000 rpm at
4°C for 10 min, before being washed with 1 volume
50 mM KPi (pH 7.0) containing 5 mM MgSO4. The
washed cell suspensions (OD600 = 0.5) were incubated for
10 min at 30°C in the presence of 20 μM ethidium brom-
ide (EB). The EB efflux was initiated by the addition of
25 mM glucose, and the cell suspension was used to
monitor the fluorescence of DNA-EB complex by a fluor-
imeter (Cary Eclipse, Australia) at 30°C using excitation
and emission wavelengths of 500 and 580 nm, respect-
ively, and slit widths of 5 and 10 nm, respectively [29].
To study the effect of ABC inhibitor Ortho-vanadate
on the accumulation of EB in OtrC expressing and
non-expressing E. coli cells [29], cells were cultured,
induced, collected and washed as described above.
Washed cells (OD600 = 0.5) were incubated for 10 min
at 30°C in the presence or absence of 0.5 mM ortho-
vanadate, followed by the addition of 20 μM ethidium
bromide (EB) along with 2 mM Mg-ATP, and the
fluorescence of EB was measured at 30°C as described
above.
OtrC knock-in and disruption in S. rimosus
The ermE*p promoter region was amplified by using
E*pf (5’CCGGAATTGTACCAGCCCGACCCGAG3’)and
E*pr (5’ CGCGGATCCGTGGAGTGGTTCTGTATCC
TACCAA 3’) as the primers to amplify a 306 bp fragment
encompassing the EcoRI and BamHI cloning sites. The en-
tire otrC gene (1,895 bp) encompassing the BamHI and
XbaI sites were amplified using genomic DNA of M4018 as
templates and otrCf (5’ CGCGGATCCCCTCTTACGAG
NAAGTCATGAAGTTCCGCCGAATGNA 3’,) and otrCr
(5’ TGCTCTAGATCAGGTCTTCTTGCGG AACTT3’)
primers, where the natural RBS sequence of otrC was intro-
duced into primer otrCf (bold). The fragments were cloned
into a pMD19-T vector for sequencing, and the fragments
were digested by the restriction enzymes after identification
and inserted into a pSET152 vector to obtain the recombin-
ant plasmid, pSET152-ermE*p-otrC (pSEC). This was iden-
tified by enzyme digesting and sequencing. Plasmid pSEC
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demethylation and then introduced into the chromosomes
of M4018 and SR16 by electroporation following standard
procedures to generate the M4018/pSEC and SR16/pSEC
mutant strains. The empty plasmid, pSET152, was intro-
duced into M4018 and SR16 to construct M4018/pSET152
and SR16/pSET152, respectively, which were used as
controls.
For the disruption of otrC, the CZ1 and CZ2 frag-
ments were amplified by PCR using two sets of primer
pairs: CZ1f (5’CCGGAATTCTGCCTGCCCGCCGTC3’)
and CZ1r (5’ CCGGATATCTCCTCGTGGTCGGCGGT
3’), CZ2f (5’ CGCGGATCCCGGCGTGGTCAACGTC
3’) and CZ2r (5’TGCTCTAGACCCTGTCCGTTCATC
NNN 3’), respectively. The kanamycin resistance cassette
(Kanr) was amplified by PCR using the primer pairs kanf
(5’ CCGGATATCTACAAGGGGTGTTATGAGCC 3’)
and kanr (5’ CGCGGATCCTTAGAAAAACTCATC
GAGCAT 3’). The final PCR products (CZ1: 993 bp,
CZ2: 992 bp, Kanr: 832 bp) were cloned into the
pMD19-T vector, and used for sequencing to confirm
the correct amplification. Fragments CZ1 and CZ2 were
used as the left bridge and the right bridge, respectively.
Three resulting DNA fragments were digested by the re-
striction enzymes and inserted into the EcoRV and XbaI
sites of the pKC1139 vector to generate pKC1139-CZ1-
Kanr-CZ2 (pKCΔotrC). The recombinant plasmid was
demethylated and introduced into either M4018 or
SR16. The screening of the otrC disruption mutants
M4018/pKCΔotrC and SR16/pKCΔotrC followed stand-
ard procedures [30]. Confirmation of the otrC disruption
was performed by the PCR amplification of kanr using
genomic DNA of the mutants as a template.Effect of OtrC expression on drug susceptibility
E.coli/pETC02 was grown in LB liquid medium with
50 μg/ml kanamycin, IPTG (1 mM) and different con-
centrations of drugs at 37°C, 170 rpm for 12 h, and then
resuspended in 1 volume of fresh LB. Then, 50 μl cell
suspension was spread immediately on the LB plates
with 50 μg/ml kanamycin and 1 mM IPTG and different
concentration of drugs, the plates were cultured at 37°C
for 12 h to determine the minimal inhibitory concentra-
tions (MICs). Experiments were performed in triplicate
using E. coli/pET28a as the negative control.
S. rimosus mutants M4018/pSEC and M4018/
pKCΔotrC were grown in TSB adding different concen-
trations of tested drugs with M4018/pSET152 at 28°C
and 220 rpm; after 30 h growth, cells were collected by
centrifugation and resuspended in 1 volume of TSB.
Then, 50 μl of fresh mycelium suspension was spread
immediately on the TSB plates with different concentra-
tion of tested drugs. The MICs were measured afterincubation for 3 d at 28°C, and experiments were per-
formed in triplicate.Effect of OtrC expression on OTC production in S .rimosus
The mutants of M4018 and SR16 were cultured on the
MS plates at 28°C for 3–5 d along with the parental
strains; spores were collected and inoculated into GYCS
medium to a final concentration of 1 × 106 spores per
ml, after they were cultured at 28°C on a rotary shaker
(260 rpm) for 72 h as the seed culture. For an assess-
ment of OTC production, 1% seed culture was trans-
ferred into SC medium and cultured at 30°C on a rotary
shaker (260 rpm) for 7 d. The OTC productivity of S.
rimosus strains were measured by high performance li-
quid chromatography analysis (HPLC). Then, 1 ml cul-
ture samples were centrifuged at 12,000 rpm for 10 min
after the pH was adjusted to pH 1.5-1.7 using 9 mol/L
HCl. The supernatants were filtered through a 0.22-μm
filter (Millipore, Bedford, MA) and 10 μl samples were
injected for analysis. Agilent 1100 HPLC system
equipped with a 5-μm C18 (Kromasil, Sweden) column
(4.6 by 200 nm) was employed for the HPLC analysis.
The mixture of 60% H2O, 10% methanol, 20% aceto-
nitrile and 10% phosphoric acid (2 mM) was used for
the mobile phase and applied with a constant flow rate
of 0.8 ml min-1 over 10 min. The OTC detection wave-
length was 350 nm [27].qRT-PCR analysis of transcription levels
The transcription level of the otrC gene was analyzed by
qRT-PCR as described previously [31]. S. rimosus cells
were collected at different developmental stages during
fermentation. Fresh tissues were used for total RNA ex-
traction immediately using the AxyPrepTM multisource
total RNA miniprep kit (Axygen, USA). The genomic
DNA was removed by DNase I digestion, and the purity
of the RNA samples was measured as the ratio of RNA
concentration (ng/μl) to protein concentration (ng/μl)
by QubitTM RNA Assay Kits and QubitTM Protein Assay
Kits (Invitrogen, CA, USA), using the QubitW 2.0
fluorometer (Invitrogen), according to the instructions
provided by the manufacturer. RNA samples (RNA:pro-
tein ratio, 1.8-2.0) were selected and examined by 3%
agarose gel electrophoresis to check their integrity prior
to qRT-PCR analysis [32,33]. First strand cDNA synthe-
sis was performed with a reverse transcription kit
(TaKaRa, Japan) according to the manufacturer’s instruc-
tions. Standard curve was consisting of a 10-fold serial
dilution series of five points which was prepared from
cDNA samples (35 ng/μl) and each dilution was tested
under a range of temperatures around the calculated
Tm of the primers used in the experiments; untran-
scribed RNA samples were used as negative controls.
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qRT-PCR conditions.
qRT-PCR was assessed using SYBRW GC Premix Ex
TaqTM kits (TaKaRa, Japan) and a CFX96TM 168 real-
time PCR detection system (Bio-Rad, USA). The total
25 μl reaction volume contained 1 μl DNA, 0.2 μM for-
ward primer, 0.2 μM reverse primer, and 1× SYBRW Pre-
mix Ex TaqTM, and the reaction conditions were as
follows: 95°C for 30 s, and 40 cycles of 95°C for 5 s, 55-
61°C for 30 s and 72°C for 30 s. Analysis of the melting
curve was performed over a range of 55°C to 95°C for
5 s at the end of the PCR cycles. Three housekeeping
genes, 16S rRNA, hrdB and G6PDH (zwf1) were used as
reference genes to normalize the data [32,34]. The opti-
mized Tm and cDNA concentration of each gene were
used for qRT-PCR analysis. The primers for qRT-PCR
were as follows: QotrCf (GTCACACGAGCGCCCTG
GT) and QotrCr (CGCCGCCGAAGACGTACAC) were
used for otrC transcriptional level analysis; QhrdBf
(CTCTGTCATGGCGCTCA) and QhrdBr (ACGTTC
TTCCACTGAGTGG) for the reference gene hrdB;
Q16Sf (AGACACGGCCCAGACTC) and Q16Sr (CTG
CTGAAAGAGGTTTACAAC) for 16S rRNA; Qzwff
(ACTGGGCCAGAACGCCCT) and Qzwfr (AGTCCAT
CGAGACGTCCCGTA) for zwf1.Additional file
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